Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Q2 2026 earnings

Reported August 5, 2026 · After market close

Revenue$39.7MBeat by $5.8M
EPS$0.14Beat by $0.03
Revenue estimate$33.9M
EPS estimate$0.11
“Zevra delivered strong MIPLYFFA performance and further established the therapy as an important treatment option for people living with Niemann-Pick disease type C. These results reflect the strength of our U.S. commercial execution. Additionally, we are pursuing access to arimoclomol for people living with NPC in Europe, and we have submitted a request for the re-examination of our Marketing Authorisation Application. Our global Expanded Access Program remains active for eligible patients, reflecting our steadfast commitment to patients and families.”
Neil F. McFarlane

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$37.1M
EPS estimate$0.14

Financials

Q2 2026

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$691.82M+70.3%
Enterprise value$548M+30.7%
P/E11.9×-142×
P/S5.1×-1.5×

Profitability

See full
Gross margin95.5%+23.5pp
Net margin42.8%+38.6pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity0×-0.5×
Current ratio5.2×-2.7×

Segments

By product

See full
MIPLYFFA$30.2M+40.5%
OLPRUVA$200.0K-33.3%

By segment

See full
Reportable Segment$39.7M+53.3%

FAQ

When did Zevra Therapeutics, Inc. report Q2 2026 earnings?
Zevra Therapeutics, Inc. (ZVRA) reported Q2 2026 earnings on August 5, 2026 after market close.
What were Zevra Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Zevra Therapeutics, Inc. reported revenue of $39.7M and eps of $0.14 for Q2 2026.
Did Zevra Therapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $33.9M by $5.8M. EPS beat the consensus estimate of $0.11 by $0.03.
How did Zevra Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 53.3% from $25.9M a year earlier and eps declined 88.4% from $1.21.
Where can I find Zevra Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001434647-26-000067) and the 10-Q periodic report (0001434647-26-000068) directly on SEC EDGAR. The filing index links above go to sec.gov.